Wednesday , May 22 2019
Home / zimbabwe / EndoPredict® predicts the benefits of chemotherapy in women with early ER-positive, HER2-negative breast cancer

EndoPredict® predicts the benefits of chemotherapy in women with early ER-positive, HER2-negative breast cancer



A new study found that many women can get unnecessary chemotherapy

SALT LAKE CITY, April 30, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that an international team of cancer researchers found that EndoPredict® the test accurately predicts which women with ER-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy. The findings of the study were published in the magazine today Breast cancer research and treatment.

"We are excited to publish our findings because ER-positive, HER2-negative breast cancer is the most common type of breast cancer and the key goal is to find out which women need endocrine therapy alone and need endocrine therapy and chemotherapy to get the best results. results, "said William J. Gradishar, MD, one of the authors of the study and head of hematology and oncology, medicine department, professor Betsy Bramsen, professor of breast cancer, and professor of medicine at the Feinberg Medical School of Northwestern University." Our study showed that the EndoPredict test can accurately identify patients who may benefit from adjuvant chemotherapy. This means that clinicians can use the EndoPredict test to personalize their care by directing chemotherapy to women with a high probability of benefit while avoiding excessive treatment of women who are unlikely to benefit. "

This study evaluated the ability of EndoPredict (EPclin) to predict the benefit of chemotherapy based on a 10-year repeat recurrence rate (ie, Metastatic Cancer) in women with ER-positive HER2 negative for five years. endocrine therapy (ET) alone or in combination with chemotherapy (ET + C). The analysis included data from 3,746 women (2,630 for ET and 1,116 for ET + C). The study found that women with high EndoPredict scores (ie> 3.3) receiving ET + C had a significantly lower risk of relapse after 10 years than ET alone (Chart 1). However, there were no significant differences between ET + C and ET in patients with low endoPredictus scores, suggesting that these women are unlikely to benefit from adjuvant chemotherapy.

"In this analysis with modern chemotherapy regimens, endoPredict high-end patients who underwent endocrine therapy and chemotherapy had significantly better results than endocrine patients alone," said Ivana Sestak, Ph.D., head of the Cancer Center, Wolfson Institute of Preventive Medicine, Queen Mary University of London. "Based on these findings, oncologists should use the EndoPredict test to decide on the best treatment for their patients."

Chart 1: EndoPredict® It assumes the benefit of chemotherapy in women with ER +, breast cancer is available at:

http://www.globenewswire.com/NewsRoom/AttachmentNg/92035128-381e-4220-91c9-1e015196dfb4

"EndoPredict is an advanced medical precision test and is the only scientific rigor test that provides excellent risk stratification for patients with both node +/- breast cancer carcinomas, to identify those patients who can safely give up prolonged endocrine therapy after five years and importantly, predict the benefits of chemotherapy, ”said Johnathan Lancaster, MD, Ph.D., Chief Medical Officer, Myriad Genetics. "EndoPredict is covered by nearly all US health insurance companies because they have realized EndoPredict's ability to address unmet health needs, improve health outcomes for women, and potentially save health systems tens of millions of dollars."

The EndoPredict test has recently been included in the National National Comprehensive Cancer Network (NCCN) Breast Cancer Directive. Follow Myriad on Twitter via @ MyriadGenetics to stay up to date with company updates and updates.

About Breast Cancer
One in eight American women will have breast cancer during their lives. Breast cancer is the second major cause of cancer death in American women. The American Cancer Society estimates in its cancer and 2019 data that more than 268,000 women will be informed that they have breast cancer in 2019.

About EndoPredict®
EndoPredict is a second generation prognostic test that helps personalized treatment planning for patients with early breast cancer. EndoPredict has been validated in more than 3,500 patients with node negative and positive node disease and is the leading prognostic method of breast in Europe. Unlike the first generation of multigenic prognostic tests, EndoPredict contains a 12-gene molecular score with known prognostic factors of tumor size and nodal status. In clinical trials, EndoPredict demonstrated its ability to predict the risk of recurrence at different times: 0-5, 5-10, and 5-15 years. EndoPredict provides clinically applicable information to doctors and patients considering the use of adjuvant chemotherapy and extended endocrine therapy.

About Myriad Genetics
Myriad Genetics Inc. is a leading personalized medical company that engages in a trusted advisor that transforms patients around the world with pioneering molecular diagnostics. Myriad reveals and commercializes molecular diagnostic tests that: determine the risk of disease, accurately diagnose disease, assess the risk of disease progression, and manage treatment decisions in six major medical disciplines where molecular diagnostics can significantly improve patient care and reduce health care costs. Myriad focuses on five critical success factors: building on a solid hereditary cancer base, expanding new product expansions, expanding new product replacement coverage, increasing international revenue from RNA kits, and improving Elevate 2020 profitability.

Myriad, Myriad logo, BART, BRACAnalysis, MyRisk, MyRisk, MyRisk, MyRisk, MyRisk, MyRisk, MyRisk, MyRisk, MyRisk, MyCrama, MyCrama, MyChoice, MyChoice, MyChoice, MyChoice HRD Myriad Genetics, Inc. or its wholly owned subsidiary in the United States and abroad. MYGN-F, MYGN-G.

Oncotype Dx is a registered trademark of Genomic Health, Inc.

Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Reform Reform Act of 1995, including a statement that clinicians can use EndoPredict to personalize their care by directing chemotherapy to women with a high probability benefit. while avoiding over-treatment of women who are unlikely to benefit; oncologists who use the EndoPredict test to decide on the best treatment for their patients; EndoPredict provides breast cancer and breast cancer breast cancer patients with excellent risk stratification and identifies those patients who can safely give up prolonged endocrine therapy after five years and anticipate the benefits of chemotherapy; EndoPredict's ability to address unmet medical needs, improve women's health outcomes, and potentially save tens of millions of dollars in healthcare systems; and Strategic Guidelines of the Company under the heading "About Myrades of Genetics". These "forward-looking statements" are based on current expectations of future event management and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those presented in, or arising from, forward-looking statements. These risks and uncertainties include, but are not limited to: the risk of reducing the sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services; the risks associated with our ability to switch from our existing product portfolio to our new tests, including unexpected costs and delays; the risks associated with decisions or changes in the level of reimbursement of government or private insurers for our tests or our ability to obtain reimbursement for our new tests at comparable levels with our existing tests; the risks associated with increased competition and the development of new competitive tests and services; the risk of not being able to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services on time or at all; the risk of not having to successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses for technologies on which our molecular diagnostic tests and pharmaceutical and clinical services are based and possible future tests and services will be discontinued or cannot be maintained under satisfactory conditions; risks associated with delays or other problems with the operation of our laboratories and our clinic; risks related to public concern about genetic testing in general or our tests in particular; risks associated with regulatory requirements or enforcement in the United States and abroad and changes in the health care system structure or healthcare payment systems; the risks associated with our ability to acquire new business collaborations or licenses and to acquire new technologies or businesses under satisfactory conditions, if at all; the risks associated with our ability to successfully integrate and benefit from any technology or business we acquire or acquire; the risks associated with our projections on our business, results of operations and financial condition; the risks associated with the potential market opportunities of our products and services; the risk that we or our licensors will not be able to protect or that third parties will violate the patented technologies that underlie our tests; risk of patent infringement or appeal regarding the validity of our patents or other intellectual property; the risks associated with changes in intellectual property laws relating to our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and abroad, such as the Supreme Court's decision in legal proceedings against us by the Association for Molecular Pathology et al . ; the risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we will not be able to meet our financial obligations under our credit or credit agreements; the risk that we will not be able to pay the amounts due under our credit or credit agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our latest Annual Report on Form 10-K for the fiscal year ended June 30, 2018, filed with the Securities and Exchange Commission, any updates to these risk factors that they are recorded from time to time in our Quarterly Reports on Form 10-Q or Current News on Form 8-K. All information in this press release is on the date of issue, and Myriad undertakes to update this information unless required by law.

Media Contact: Ron Rogers Investor Contact: Scott Gleason
(801) 584-3065 (801) 584-1143
rrogers@myriad.com sgleason@myriad.com


Source: Myriad Genetics, Inc.


Source link